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CN1 Global Health Research Initiative, Ottawa, Canada; ANVISA - OPS, Brasilia,
Brazil
CN2 Consejo Mexicano Contra el Tabaquismo en colaboracio´n con el Instituto
Nacional de Salud Pu´blica, Me´xico, D.F., Mexico
CN3 None
CN4 None
CV1 Boehringer Ingelheim, Bogota, Colombia
CV2 Eli Lilly and Company, Me´xico, D.F., Mexico
CV3 None
CV4 None
EX2 AstraZeneca Pharmaceuticals, Macclesfield, UK
EX3 None
EX4 None
HS1 Pan American Health Organization, Washington DC, USA
HS2 Convenio OPS / MPS Colombia, Bogota, Colombia
HS3 Pan American Health Organization/World Health Organization, through its
Country Office, Belize, Belize
HS4 Consejo Mexicano Contra el Tabaquismo en colaboracio´n con el Instituto
Nacional de Salud Pu´blica, Me´xico, DF, Mexico
IN1 Pfizer S.A. de C.V., Me´xico, D.F., Mexico
IN2 Capes, Brası´lia, Brazil
IN3 None
IN4 Pfizer Inc, New York, NY, USA
PCN1 GlaxoSmithKline, Wavre, Belgium
PCN2 None
PCN3 Novartis, Bogota, Colombia
PCN4 Novartis, Bogota, Colombia
PCN5 Novartis, Bogota´ D.C., Colombia
PCN6 BMS, Bogota, Colombia
PCN7 None
PCN8 None
PCN9 Amgen Mexico, Mexico City, Mexico
PCN10 Bayer Colombia, Bogota, Colombia
PCV1 Covidien, Mansfield, MA, USA
PCV2 AstraZeneca, Mexico D.F., Mexico
PCV3 AstraZeneca, Sao Paulo, Brazil
PCV4 CONACYT, Me´xico, D.F., Mexico
PCV5 Bayer Brasil, Sa˜o Paulo, Brazil; MedInsight Evideˆncias, Sa˜o Paulo, Brazil
PCV6 Bayer Brasil, Sa˜o Paulo, Brazil; MedInsight Evideˆncias, Sa˜o Paulo, Brazil
PCV7 Eli Lilly and Company, Me´xico, D.F., Mexico
PCV8 Bayer Brasil, Sa˜o Paulo, Brazil; MedInsight Evideˆncias, Sa˜o Paulo, Brazil
PCV9 None
PCV10 Sandoz Mexico, Mexico City, Mexico
PDB2 None
PDB3 Eli Lilly and Company, Me´xico, D.F., Mexico
PDB4 Secretaria de Estado da Sau´de de Minas Gerais, Belo Horizonte, Brazil
PDB5 Johnson & Johnson Medical Mexico, Mexico City, Mexico
PDB6 Novo Nordisk International Affairs, Buenos Aires, Argentina
PDB7 Bristol-Myers Squibb, Buenos Aires, Argentina
PDB8 CONACYT, Me´xico D.F., Mexico
PDB9 Novonordisk Colombia, Bogota, Colombia
PDB10 Eli Lilly, Me´xico, D.F., Mexico
PDB11 ELi Lilly and Company, Me´xico, D.F., Mexico
PGI1 Cellerix SA, Tres Cantos, Spain
PGI2 Abbott Laboratories, Abbott Park, Chicago, IL, USA
PGI3 BMS, Bogota, Colombia
PGI4 UCB, Braine l, Alleud, Belgium
PHP1 None
PHP2 None














PHP18 Instituto Mexicano del Seguro Social, Mexico, D.F., Mexico
PHP19 None
PHP20 MCT/CT-Sau´de and MS/SCTIE/DECIT, via CNPq (Edital 67/2009) - Public
funding, Brasilia, Brazil
PHP21 None
PHP22 James & Esther King Biomedical Research/ The Florida Department of
Health, Lee’s Summit, MO, USA
PHP23 None










PHP35 Pfizer, Sao Paulo, Brazil
PHP36 Double Helix Consulting, London, UK
PHP37 Double Helix Consulting, London, UK
PHP38 Medtronic, Doral, FL, USA
PHP39 Double Helix Consulting, London, UK
PHP40 None
PHP41 GlaxoSmithKline, Bratislava, Slovak Republic
PHP42 Universidad Central de Venezuela, Caracas, Venezuela
PHP43 Scholarship Beca Chile, Santiago, Chile
PHP44 Eli Lilly and Co., Indianapolis, IN, USA




PHP50 London School of Hygiene and Tropical Medicine, London, UK
PHP51 None
PIH1 Bayer, Mexico, D.F., Mexico
PIH2 None
PIH3 MedInsight Evideˆncias, Sa˜o Paulo, Brazil
PIH4 Bayer, Mexico, D.F., Mexico
PIH5 GlaxoSmithKline, Wavre, Belgium
PIN1 Bristol-Myers Squibb, Wallingford, CT, USA
PIN2 None
PIN3 None
PIN4 Pfizer Inc, New York, NY, USA
PIN6 Pfizer S.A: de C.V., Me´xico, D.F., Mexico
PIN7 Pfizer, La Aurora, Costa Rica
PIN8 None
PIN10 None
PIN11 GlaxoSmithKline, Rio de Janeiro, Brazil
PIN12 None
PMH1 Janssen, Beerse, Belgium
PMH2 None
PMH3 Janssen de Me´xico, Me´xico, D.F., Mexico
PMH4 ELi Lilly, Mexico, D.F., Mexico
PMH5 Janssen, Bogota, Colombia
PMS1 Pfizer S.A. de C.V., Me´xico, D.F., Mexico
PMS2 None
PMS3 Pfizer, Mexico, D.F., Mexico
PMS4 Pfizer Pharmaceutics inc., New York, NY, USA
PMS5 Productos Roche, S.A. d C.V., Me´xico, Mexico
PMS6 None
PMS7 Abbott, Bogota, Colombia
PMS8 Pfizer, La Aurora, Costa Rica
PMS9 BMS, Bogota, Colombia
PMS10 Eli Lilly, Me´xico, D.F., Mexico
PMS11 Fapemig, Belo Horizonte, Brazil
PMS12 Grupo Roche, S.A. de C.V., Me´xico, D.F., Mexico
PMS13 Abbott Laboratories, Abbott Park, IL, USA
PND3 None
PND4 Consejo Mexicano Contra el Tabaquismo en colaboracio´n con el Instituto
Nacional de Salud Pu´blica, Me´xico, D.F., Mexico
PRM2 None
PRM3 None
PRM4 Genentech, Inc., South San Francisco, CA, USA
PRM5 Universidad Nacional de Colombia, Bogota, Colombia
PRM6 None
A571V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 5 7 1 - A 5 7 2
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
PRS1 GSK, Mexico, Mexico
PRS2 Consejo Mexicano Contra el Tabaquismo en colaboracio´n con el Instituto
Nacional de Salud Pu´blica, Me´xico, DF, Mexico
PRS3 Consejo Mexicano Contra el Tabaquismo, Mexico, D.F., Mexico
PRS4 Abbott Laboratories de Mexico, Mexico City, Mexico
PRS5 Pfizer, La Aurora, Costa Rica
PRS6 GSK, Mexico, D.F., Mexico
PRS7 Gru¨nenthal Colombiana S.A., Bogota´, Colombia
PRS8 Universidad de La Sabana, Chia, Colombia
PRS9 Fundacio´n Bloomberg, New York, NY, USA
PR1 GlaxoSmithKline, Tres Cantos, Spain
PR2 National Institute for Health Research, London, UK
PR3 Ministry of Health, Santiago, Chile
PR4 Universidad de Guadalajara, CD. Guzman, Mexico
PSS1 TECNOLOGICOS DALUP S. DE R.L. DE C.V., Me´xico, D.F., Mexico
PSS2 None
PSS3 Sandoz Mexico, Mexico City, Mexico
PSS4 PFSA, Boulogne, France
PSY1 None
PSY2 None
PSY3 Johnson & Johnson Medical Mexico, Mexico City, Mexico
PSY4 None
PSY5 Gru¨nenthal Colombiana S.A., Bogota´, Colombia
PSY6 Gru¨nenthal Colombiana S.A., Bogota´, Colombia
PSY7 Amgen Limited, Thousand Oaks, CA, USA
PSY8 None




PUK1 Abbott Laboratories, Mexico City, Mexico




QA1 GSK, Buenos Aires, Argentina
QA2 Productos Roche Colombia, Bogota, Colombia
QA3 Boehringer Ingelheim, Bogota, Colombia
QA4 MEDTRONIC, Mexico City, Mexico
RM1 Mexican Ministry of Health , Mexico City, Mexico; Panamerican Health
Organization, Mexico City, Mexico; National Council on Science and
Technology, Mexico City, Mexico
RM2 None
RM3 None
RM4 Fondo Nacional de REcursos, Montevideo, Uruguay
TP1 Merck and Co., Inc., Whitehouse Station, NJ, USA
TP2 Bristol-Myers Squibb de Me´xico, Mexico, D.F., Mexico
TP3 Bristol-Myers Squibb, Mexico, Mexico
VA1 Ministerio de la Proteccion Social, Bogota, Colombia
VA2 Pfizer S.A., Bogota, Colombia
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